Skip to main content
. 2020 Jun 20;227:47–55. doi: 10.1016/j.ahj.2020.06.011

Table II.

Diagram of data acquisition

Item Baseline Hospitalized treatment period
Follow-up time point
2 h 12 h 24 h 72 h 7 d/discharge 1 m 3 m 6 m 9 m 12 m
History
Inclusion/exclusion criteria
Informed consent
Drug distribution
ECG
cTNI and CKMB
NT-ProBNP
Hematology
Urinalysis
Stool occult blood test
Echocardiogram
Holter
Evaluate clinical end point events
Outpatient follow-up

cTNI, cardiac troponin I; CKMB, creatine kinase–muscle/brain; NT-ProBNP, N-terminal pro–B-type natriuretic peptide.